JPRN-UMIN000002618已完成未知
Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer - AMR+CBDCA for refractory relapse SCLC
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Severe co-morbidities 2. Symptomatic brain metastasis 3. Massive effusion that require drainage 4. Pregnant woman
研究者
相似试验
已完成
不适用
Phase II study of amrubicin combined with carboplatin for unresectable invasive thymoma or thymic carcinomaThymoma/Thymic carcinomaJPRN-UMIN000002619Tohoku University Hospital40
已完成
2 期
A phase II study of carboplatin and amurubicin with a biweekly schedule in patients with advanced squamous cell lung canceron-Small Cell Lung Cancer,Squamous cell lung cancerJPRN-UMIN000007102ational Hospital Organization Kyushu Medical Center Department of Respiratory Medicine25
已完成
2 期
A phase II study of amrubicin for previously treated small cell lung cancerFor patients with recurrent small cell lung cancerJPRN-UMIN000001752Gunma University Hospital35
已完成
1 期
Phase 1-2 Study of Amrubicin plus Nedaplatin for Advanced Non-Small-Cell Lung Canceron-Small-Cell Lung CancerJPRN-UMIN000003282agasaki University Hospital35
已完成
2 期
Phase II study of amrubicin for previously treated advanced non-small cell lung cancerRecurrent non-small cell lung cancerJPRN-UMIN000001751Gunma University Hospital35